The Russian Direct Investment Fund (RDIF) has reported that the Sputnik V vaccine demonstrated a 97.2% efficacy against Covid-19 during the vaccination campaign in Belarus.

Based on an established and well-studied platform of human adenoviral vectors, Sputnik V leverages heterogeneous boosting which uses two separate vectors for two shots.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

This boosting approach offers immunity for an extended duration than vaccines that use the same delivery mechanism for both vaccines.

The efficacy of the vaccine was assessed based on data from more than 860,000 individuals inoculated between January and July this year.

The latest real-world data of the Ministry of Health of the Republic of Belarus showed that Sputnik V was demonstrated to have increased efficacy and a greater safety profile against Covid-19.

Furthermore, no severe adverse events or deaths linked to the vaccine were reported, RDIF noted.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In December 2020, Belarus became the first outside Russia to register Sputnik V and use it for inoculation of the population.

RDIF and partners enabled the technology transfer to localise the manufacture of Sputnik V by Belarus-based company Belmedpreparaty, which is currently producing the vaccine.

In April 2021, Sputnik V produced in Belarus was authorised by the country’s Ministry of Health.

Russia’s single-dose Sputnik Light vaccine was registered in Belarus during the same month.

Sputnik Light contains the first component of Sputnik V and is based on human adenovirus serotype 26.

The Gamaleya National Research Center of Epidemiology and Microbiology and the RDIF reported that Sputnik V showed a 97.6% efficacy.

This was based on the analysis of data on the disease infection rate among people receiving both shots of the vaccine.